Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

17 results about "Meningitis" patented technology

An infection of meninges, protective tissue of the brain.

Methods of treating or controlling cytotoxic cerebral edema

The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and / or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g., neurosurgery, endovascular clot removal, spinal tap, aneurysm repair, or deep brain stimulation, as well as retinal edema), as well as hyponatremia and excess fluid retention, and diseases such as epilepsy, retinal ischemia and other diseases of the eye associated with abnormalities in intraocular pressure and / or tissue hydration, myocardial ischemia, myocardial ischemia / reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines, as well as to novel assays for identifying aquaporin inhibitors.
Owner:AEROMICS INC

Use of NLRP3 inhibitor for treating encephalitis or meningitis

PCT designated stageWO2026082105A1Organic active ingredientsNervous disorderEncephalitisPharmaceutical drug
Use of an NLRP3 inhibitor for treating encephalitis or meningitis. Specifically, provided is use of a compound represented by formula (I) or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating encephalitis or meningitis, wherein each substituent is as defined in the description.
Owner:QINGDAO BORSON TAI TECHNOLOGY CO LTD

A new group B meningococcal outer membrane protein bifunctional vector

ActiveCN120241991BBacterial antigen ingredientsAntibacterial agentsAdjuvantPrimary immunization
The application discloses a novel group B meningococcal outer membrane protein bifunctional carrier, relates to the technical field of biopharmaceutical processes, and discloses a group B meningococcal outer membrane protein bifunctional carrier and application of the bifunctional carrier in a meningitis combined vaccine. The bifunctional carrier is human H factor binding protein fHbp, and comprises two kinds of recombinant proteins BA and BB, and the amino acid sequences of the two kinds of recombinin proteins are SEQ ID No. 62 and SEQ ID No. 63 respectively. The BA protein is coupled with group A capsule polysaccharide to form a group A combined vaccine, the BB protein is coupled with group C capsule polysaccharide to form a group C combined vaccine, and the two are mixed to form a group ABC triple vaccine. Each dose of the triple vaccine contains 40 μg of group A / C polysaccharide, 160 μg of BA / BB protein in total and 1.0 mg of aluminum adjuvant. The BA and BB proteins are expressed by E. coli, are broken by high-pressure homogenization, and are purified by anion exchange chromatography, and the purity is greater than or equal to 95%. The triple vaccine can simultaneously induce immune responses to groups A, B and C of meningitis, the serum bactericidal titer is greater than or equal to 1:32 after primary immunization, and the titer is maintained for more than 56 days after three immunizations.
Owner:BEIJING LUZHU BIOTECH +1

Polymer with side chain containing biguanidyl as well as preparation method and application of polymer

The invention relates to a polymer with a side chain containing biguanidyl as well as a preparation method and application of the polymer. The polymer has efficient antibacterial activity and / or anti-tumor activity, can penetrate the blood brain barrier, has application potential in treatment of meningitis and / or brain tumor and other diseases, and has excellent application prospects in the fields of drug delivery, drug synergy, drug modification, gene delivery and the like.
Owner:EAST CHINA UNIV OF SCI & TECH

Rapid meningitis diagnosis system based on combination of SERS (Surface Enhanced Raman Scattering) technology and machine learning method

The invention belongs to the technical field of machine learning auxiliary diagnosis, and particularly relates to a meningitis rapid diagnosis system based on the combination of an SERS technology and a machine learning method. The system comprises: an input module, which is used for inputting SERS spectral data of cerebrospinal fluid; the preprocessing module is used for preprocessing the SERS spectrum data; and the prediction module is used for calculating the preprocessed SERS spectral data through a machine learning model to obtain a meningitis classification prediction result. According to the method and the system, the SERS technology and the machine learning method are combined for the first time, the method and the system for rapidly and automatically diagnosing the meningitis are realized, and the method and the system have the advantages of simplicity, rapidness, accuracy, capability of carrying out subtype classification and the like, and have a good application prospect in clinical diagnosis of the meningitis, particularly in an early screening process.
Owner:WEST CHINA HOSPITAL SICHUAN UNIV

Composition for detecting meningitis pathogens, kit and application

The invention relates to the technical field of biological detection, and discloses a composition for detecting meningitis pathogens, a kit and application. The composition comprises detection primers and selectable probes for 14 pathogens causing meningitis, multiple pathogens can be detected at the same time through the multiple PCR technology, the use amount of samples is reduced, and meanwhile the composition has the advantages of being high in detection speed, efficiency, accuracy and sensitivity and the like.
Owner:HUNAN SHENGWEI GENE TECH

A diterpenoid compound, its preparation method and anti-inflammatory use thereof

The application discloses a novel diterpenoid compound with anti-inflammatory activity separated from Origanum vulgare Linn. 20 H 18 O4, and a structural formula is as shown in formula I. A preparation method of the compound comprises the following steps: crushing dried medicinal materials of Origanum vulgare Linn., extracting by using ethanol, concentrating under reduced pressure to obtain total extract; after extraction by using petroleum ether, the target compound is obtained through silica gel column chromatography, Sephadex LH-20 gel column chromatography and preparation type high performance liquid phase chromatography separation and purification. In vitro anti-inflammatory experiments show that the compound can significantly inhibit NO generation in a LPS-induced RAW264.7 macrophage model, and the inhibition rate reaches 62.97%, and the compound shows good anti-inflammatory activity. The compound can be used for preparing medicines for preventing or treating inflammatory diseases such as enteritis, hepatitis and meningitis.
Owner:GANNAN MEDICAL UNIV

Quantum dot modified group B neisseria meningitidis and vaccine preparation method thereof

The invention provides quantum dot modified group B neisseria meningitidis and a preparation method of a vaccine of the quantum dot modified group B neisseria meningitidis. The preparation method comprises the following steps: taking corn straws and sunflower straws as a straw mixture according to a weight ratio of (1-1.5): 1, putting the straw mixture, an escherichia coli DH5alpha cell membrane and urea into water according to a weight ratio of 100: 100: 1, carrying out high-temperature heating reaction, and filtering and dialyzing reactants to prepare aminated quantum dots; extruding the aminated quantum dots and a group B neisseria meningitidis cell membrane through a liposome extruder according to a weight ratio of (8-10): 1, and centrifuging to obtain cell membrane hybrid aminated quantum dots; and co-incubating the cell membrane hybrid aminated quantum dots and the group B neisseria meningitidis to obtain the cell membrane hybrid aminated quantum dots. The group B neisseria meningitidis is modified by adopting the specific quantum dots, the toxicity of the modified group B neisseria meningitidis is obviously reduced, and the modified group B neisseria meningitidis is expected to be applied to related fields of vaccines and the like.
Owner:NANCHANG UNIV

Meningitis precise auxiliary typing method based on machine learning model, electronic equipment and storage medium

The invention discloses an accurate auxiliary meningitis typing method based on a machine learning model, electronic equipment and a storage medium, and the method comprises the steps: selecting medical detection items as features, and combining the features to construct a feature subset; constructing a meningitis subdivision discrimination framework, and disassembling meningitis diagnosis requirements into nine mutually independent binary discrimination tasks; taking the feature subset as input, executing each binary discrimination task to construct a training task, and training an independent machine learning model; obtaining a binary discrimination task selected by a doctor and a binary discrimination task selected by the doctor; and respectively calling independent machine learning models for execution, and outputting auxiliary typing discrimination. According to the accurate meningitis typing method based on multi-task discrimination of the machine learning model, clinicians are helped to judge meningitis categories by using a machine learning method, so that accurate and effective diagnosis and treatment are provided for patients in time.
Owner:SHANGHAI HUIHAO YISHENG INFORMATION TECHNOLOGY CO LTD

Establishment method of model for inflammation of mouse brain microvascular endothelial cells infected by haemophilus parasuis

The invention discloses a method for establishing a model for inflammation of mouse brain microvascular endothelial cells infected by haemophilus parasuis, which is used for simulating the process of porcine meningitis caused by haemophilus parasuis infection by using the mouse brain microvascular endothelial cells infected by haemophilus parasuis and researching the pathogenesis of the porcine meningitis caused by haemophilus parasuis. The optimal MOI of mouse brain microvascular endothelial cells infected by haemophilus parasuis is 1, the optimal infection time is 6 h, under the condition, the inflammatory factor level of the cells is remarkably increased, and the success rate of the cell inflammation model construction method is higher.
Owner:WUHAN POLYTECHNIC UNIVERSITY

A group b meningococcal vaccine and uses thereof

PendingCN122351450AHigh antibody titersBroad protective effectTGE VACCINEInfection induced
This invention discloses a serogroup B meningococcal vaccine and its application. The serogroup B meningococcal vaccine contains one or more recombinant proteins with amino acid sequences as shown in SEQ ID NO:1-7. The vaccine against serogroup B meningococcus of this invention induces a strong humoral immune response and broad-spectrum protective efficacy. Compared with existing technologies, the vaccine against serogroup B meningococcus of this invention has high antibody titers and broad protective efficacy. It has broad application value and positive social benefits in preventing diseases caused by serogroup B meningococcus infection and alleviating severe cases.
Owner:JIANGSU KUNLI BIOPHARMACEUTICAL CO LTD +1

Composition for detecting pathogens, and kit and method therefor

Provided is a composition for detecting multiple encephalitis / meningitis / respiratory pathogens. The composition includes primer sequences for the pathogens as shown in SEQ ID NOs: 1-7, 9-23 and 25-32, in which SEQ ID NOs: 1-7 and 9-16 carry fluorescent reporter groups. In addition, the present invention further provides a use of the foregoing composition in the preparation of a kit, and a related kit and a method for using the same.
Owner:SANSURE BIOTECH INC

Application of acetylcholine receptor agonist in treatment of meningitis

PendingCN121041449AAntibacterial agentsOrganic active ingredientsAcetylcholine receptorAgonist
The invention discloses an application of an acetylcholine receptor stimulant in treatment of meningitis. It is found for the first time that the acetylcholine receptor stimulant GTS-21 can prevent and treat meningitis and can also prevent and treat cognitive impairment caused by meningitis, a new thought is provided for effective treatment of meningitis and memory impairment caused by meningitis, and the acetylcholine receptor stimulant GTS-21 has wide application prospects.
Owner:ACADEMY OF MILITARY MEDICAL SCIENCES

Diterpenoid compound as well as preparation method and anti-inflammatory application thereof

The invention discloses a novel diterpenoid compound which is separated from origanum vulgare and has anti-inflammatory activity, the molecular formula of the diterpenoid compound is C20H18O4, and the structural formula of the diterpenoid compound is shown as a formula I. The preparation method of the compound comprises the following steps: crushing a dried medicinal material of origanum vulgare, extracting with ethanol, and concentrating under reduced pressure to obtain a total extract; and after extracting with petroleum ether, separating and purifying through silica gel column chromatography, Sephadex LH-20 gel column chromatography and preparative high performance liquid chromatography to obtain a target compound. In-vitro anti-inflammatory experiments show that the compound can significantly inhibit NO generation in an LPS-induced RAW264.7 macrophage model, the inhibition rate reaches 62.97%, and good anti-inflammatory activity is shown. The compound can be used for preparing medicines for preventing or treating inflammatory diseases such as enteritis, hepatitis and meningitis.
Owner:GANNAN MEDICAL UNIV

A process for the preparation of a group a meningococcal capsular polysaccharide conjugate

ActiveCN113730568BAntibacterial agentsNervous disorderPolysaccharide bindingUltrafiltration
This application relates to the technical field of vaccine conjugates, specifically to a method for preparing a polysaccharide conjugate of group A meningococcal capsular polysaccharide, including the preparation of polysaccharide derivatives, mixing ratio, conjugation reaction, aging treatment, ultrafiltration and sterilization steps. This application eliminates the pH adjustment and conjugate purification steps in the activation process by optimizing the process parameters, but the quality of the harvested polysaccharide conjugate still meets the national standards, thereby simplifying the preparation process of polysaccharide conjugates and shortening the preparation cycle of polysaccharide conjugates.
Owner:ZHEJIANG VACIN BIO PHARMA LTD

Explainable ai system for ICU diagnosis prediction

PCT designated stageWO2026143167A1Aortic dissectionDiagnosis laboratory
An explainable artificial intelligence system for early prediction of missed severe diagnoses in intensive care unit patients is provided. The system comprises a data processing module configured to receive and process electronic health record data including patient demographics, vital signs, laboratory results, and diagnostic codes. A machine learning module with ensemble, deep learning, and large language models analyzes processed data to predict likelihood of severe diagnoses including acute myocardial infarction, acute pulmonary embolism, bacterial pneumonia, aortic dissection, meningitis, spinal abscess, bacterial endocarditis, and arterial thromboembolism. An explainability module generates feature importance rankings and provides interpretable explanations for predictions.
Owner:NORTHEASTERN UNIV (US)